CD40 and neoplasm: Particularly noteworthy was the demonstration by van Mierlo et al. that agonistic anti-CD40 antibody leads to the rejection of tumors formed by malignant cells that themselves lack the CD40 receptor, indicating that a primary effect of this treatment is on the host immune response and not necessarily on the tumor cells themselves [12].